DDInter1763 DDInter119
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Temsirolimus {u} (Compound) treats {v} (Disease) kidney cancer
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
Temsirolimus {u} (Compound) upregulates {v} (Gene) MICU1
Temsirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Temsirolimus {u} (Compound) downregulates {v} (Gene) TFDP1
Temsirolimus {u} (Compound) causes {v} (Side Effect) Febrile neutropenia
Temsirolimus (Compound) resembles Everolimus (Compound)
Temsirolimus (Compound) treats kidney cancer (Disease)
Temsirolimus (Compound) binds CYP3A4 (Gene)
Temsirolimus (Compound) upregulates MICU1 (Gene)
Temsirolimus (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Temsirolimus (Compound) downregulates TFDP1 (Gene)
Temsirolimus (Compound) causes Febrile neutropenia (Side Effect)